Search results
Exxon hit with $725.5 million verdict over mechanic's leukemia diagnosis
Reuters· 6 days ago, opens new tab to pay $725.5 million to a former mechanic who claimed toxic chemicals in the...
Phila. Jury Hits ExxonMobil With $725.5M Verdict Over Carcinogen in Gasoline | The Legal...
Law.com· 6 days agoA Philadelphia state court jury hit ExxonMobil with a $725.5 million verdict Thursday for failing to...
Brookfield cancer patient gets ‘a second chance on life’ with stem cells from a Canadian athlete
The News-Times· 3 days agoSubmission of a sample to a national donor program sparked an unexpected connection between a...
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress - Innate Pharma (NASDAQ:IPHA)
Benzinga· 2 days agoTwo abstracts on SAR443579 (IPH6101), ANKET® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate's
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 3 days agoAML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor ...
Tharini Nagarkar, Connor Raine are Ideal Bonaventure Students for 2024
Olean Times Herald· 4 days agoTharini Nagarkar, a health and society major from Danville, California, and Connor Raine, a sports...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoHONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days ago– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation – – SL
Vor Biopharma’s (VOR) Market Outperform Rating Reiterated at JMP Securities
ETF DAILY NEWS· 21 hours agoJMP Securities reiterated their market outperform rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report released on Monday, Benzinga reports. They currently have a ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 1 day agoPreliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell